Featured Publications
Distinguishing features of long COVID identified through immune profiling
Klein J, Wood J, Jaycox J, Dhodapkar R, Lu P, Gehlhausen J, Tabachnikova A, Greene K, Tabacof L, Malik A, Silva Monteiro V, Silva J, Kamath K, Zhang M, Dhal A, Ott I, Valle G, Peña-Hernández M, Mao T, Bhattacharjee B, Takahashi T, Lucas C, Song E, McCarthy D, Breyman E, Tosto-Mancuso J, Dai Y, Perotti E, Akduman K, Tzeng T, Xu L, Geraghty A, Monje M, Yildirim I, Shon J, Medzhitov R, Lutchmansingh D, Possick J, Kaminski N, Omer S, Krumholz H, Guan L, Dela Cruz C, van Dijk D, Ring A, Putrino D, Iwasaki A. Distinguishing features of long COVID identified through immune profiling. Nature 2023, 623: 139-148. PMID: 37748514, PMCID: PMC10620090, DOI: 10.1038/s41586-023-06651-y.Peer-Reviewed Original ResearchConceptsLong COVIDSARS-CoV-2Infection syndromeExaggerated humoral responseSoluble immune mediatorsEpstein-Barr virusPost-exertional malaiseCross-sectional studyHigher antibody responseImmune mediatorsImmune phenotypingImmune profilingHumoral responseAntibody responseLymphocyte populationsCOVID statusUnbiased machineCortisol levelsLC statusRelevant biomarkersViral pathogensSyndromeCOVIDFuture studiesBiological featuresEnvironmental surveillance for COVID-19 using SARS-CoV-2 RNA concentration in wastewater – a study in District East, Karachi, Pakistan
Ansari N, Kabir F, Khan W, Khalid F, Malik A, Warren J, Mehmood U, Kazi A, Yildirim I, Tanner W, Kalimuddin H, Kanwar S, Aziz F, Memon A, Alam M, Ikram A, Meschke J, Jehan F, Omer S, Nisar M. Environmental surveillance for COVID-19 using SARS-CoV-2 RNA concentration in wastewater – a study in District East, Karachi, Pakistan. The Lancet Regional Health - Southeast Asia 2023, 20: 100299. PMID: 38234701, PMCID: PMC10794106, DOI: 10.1016/j.lansea.2023.100299.Peer-Reviewed Original Research
2022
The balancing role of distribution speed against varying efficacy levels of COVID-19 vaccines under variants
Kim D, Keskinocak P, Pekgün P, Yildirim İ. The balancing role of distribution speed against varying efficacy levels of COVID-19 vaccines under variants. Scientific Reports 2022, 12: 7493. PMID: 35523832, PMCID: PMC9075929, DOI: 10.1038/s41598-022-11060-8.Peer-Reviewed Original ResearchConceptsOverall public health impactInfection attack rateCOVID-19 vaccineSARS-CoV-2Public health impactVaccine effectivenessAdverse outcomesMultiple vaccinesInitial efficacySuccessful immunization strategyImmunization strategiesVaccineLow-income countriesAttack rateEfficacyCOVID-19COVID-19 pandemicHealth impactsInfection spreadRecovered-deceased [SI(Q/F)RD] modelEfficacy levelsPandemicHospitalizationVaccinationVariantsAssociation of Child Masking With COVID-19–Related Closures in US Childcare Programs
Murray TS, Malik AA, Shafiq M, Lee A, Harris C, Klotz M, Humphries JE, Patel KM, Wilkinson D, Yildirim I, Elharake JA, Diaz R, Reyes C, Omer SB, Gilliam WS. Association of Child Masking With COVID-19–Related Closures in US Childcare Programs. JAMA Network Open 2022, 5: e2141227. PMID: 35084484, PMCID: PMC8796014, DOI: 10.1001/jamanetworkopen.2021.41227.Peer-Reviewed Original ResearchConceptsCOVID-19 casesLower riskImportant public health policy implicationsCOVID-19-related closuresPublic health policy implicationsChildren 2 yearsElectronic survey studyCenter-based childcare programsHealth policy implicationsSARS-CoV-2Survey studyChildcare professionalsMAIN OUTCOMEProgram closureHealth policyStudy periodRobust SEsBaselineChildcare programsCOVID-19Young childrenChildcare settingsChildrenPhysical distancingAssociation
2021
Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity
Lucas C, Vogels CBF, Yildirim I, Rothman JE, Lu P, Monteiro V, Gehlhausen JR, Campbell M, Silva J, Tabachnikova A, Peña-Hernandez MA, Muenker MC, Breban MI, Fauver JR, Mohanty S, Huang J, Shaw A, Ko A, Omer S, Grubaugh N, Iwasaki A. Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. Nature 2021, 600: 523-529. PMID: 34634791, PMCID: PMC9348899, DOI: 10.1038/s41586-021-04085-y.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 variantsMRNA vaccine-induced immunityT-cell activation markersSARS-CoV-2 antibodiesSecond vaccine doseVaccine-induced immunityCell activation markersT cell responsesHigh antibody titresSARS-CoV-2Vaccine boosterVaccine doseActivation markersVaccine dosesHumoral immunityAntibody titresMRNA vaccinesVitro stimulationNeutralization capacityNeutralization responseCell responsesE484KNucleocapsid peptideAntibody-binding sitesGreater reduction